Science Explorer Back to mapMap
Discussion
Company · Boston · United States

Acetylon Pharmaceuticals (United States)

acetylon.comROR OpenAlex
Research works
41
▼ 49% vs 2018-21
Citations
840
20.4 per fractional work
Top-10% rate
14.1%
all institutions 10.0%
Open access
24%
world 40%
International
12%
world 18%
Acetylon Pharmaceuticals (United States)

Not ranked overall: Acetylon Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Acetylon Pharmaceuticals (United States) work in?

In all years, 62% of research at Acetylon Pharmaceuticals (United States) is in Life Sciences, 38% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (59%), Medicine (37%), Neuroscience (2%). It does 3.1× the world's share of Life Sciences.

Life Sciences: 26 fractional works · 62.0% of its workBiochemistry, Genetics and Molecular Biology: 24 fractional works · 58.9% of its workMolecular Biology: 24 fractional works · 58.3% of its workGenetics: 0 fractional works · 0.5% of its workNeuroscience: 1 fractional works · 1.7% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.9% of its workNeurology: 0 fractional works · 0.4% of its workDevelopmental Neuroscience: 0 fractional works · 0.2% of its workCognitive Neuroscience: 0 fractional works · 0.2% of its workImmunology and Microbiology: 1 fractional works · 1.4% of its workImmunology: 1 fractional works · 1.4% of its workHealth Sciences: 15 fractional works · 37.5% of its workMedicine: 15 fractional works · 36.9% of its workHematology: 4 fractional works · 10.3% of its workOncology: 4 fractional works · 10.3% of its workGenetics: 3 fractional works · 6.3% of its workNeurology: 1 fractional works · 2.5% of its workPulmonary and Respiratory Medicine: 1 fractional works · 1.4% of its workPhysiology: 0 fractional works · 1.1% of its workInfectious Diseases: 0 fractional works · 1.0% of its workPathology and Forensic Medicine: 0 fractional works · 0.9% of its workEpidemiology: 0 fractional works · 0.6% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.5% of its workRheumatology: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.4% of its workEmergency Medicine: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workDentistry: 0 fractional works · 0.4% of its workOral Surgery: 0 fractional works · 0.2% of its workPeriodontics: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.0% of its workHealth Professions: 0 fractional works · 0.2% of its workPhysical Sciences: 0 fractional works · 0.5% of its workChemistry: 0 fractional works · 0.5% of its workOrganic Chemistry: 0 fractional works · 0.5% of its workALL ITS WORKAcetylonPharmaceuticals…41fractional works, all years
Life Sciences62%Physical Sciences1%Health Sciences38%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 7 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2458.9%
    2. Neuroscience11.7%
    3. Immunology and Microbiology11.4%
    1. Medicine1536.9%
    2. Dentistry00.4%
    3. Health Professions00.2%
    1. Chemistry00.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Acetylon Pharmaceuticals (United States)?

Ranked on the quality score, Matthew B. Jarpe, Min Yang and Steven N. Quayle lead among researchers whose main affiliation is Acetylon Pharmaceuticals (United States).

  1. 1 Matthew B. Jarpe United States · #238,168 worldwide 7.2k citations · 57 works
  2. 2 Min Yang United States · #327,363 worldwide 2.6k citations · 43 works
  3. 3 Steven N. Quayle United States · #632,009 worldwide 2.4k citations · 123 works
  4. 4 Simon S. Jones United States · #644,634 worldwide 5.4k citations · 84 works
  5. 5 John H. van Duzer United States · #1,183,242 worldwide 1.6k citations · 24 works
  6. 6 Olga Golonzhka United States · #1,276,326 worldwide 1.3k citations · 28 works
  7. 7 David Tamang United States · #1,311,657 worldwide 2.3k citations · 54 works
  8. 8 Jeffrey R. Shearstone United States · #1,444,379 worldwide 1.5k citations · 34 works
  9. 9 Min Yang United States · #3,219,429 worldwide 150 citations · 36 works
All ranked researchers at Acetylon Pharmaceuticals (United States)

What are the most cited papers from Acetylon Pharmaceuticals (United States)?

The most cited paper from Acetylon Pharmaceuticals (United States) is "Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma" (Loredana Santo, Teru Hideshima, Andrew L. Kung et al., 2012), with 613 citations. Next come "HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients" (389) and "Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance" (306).

Most cited papers
#PaperReleasedCitations
1 Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood Open access 20 Jan 2012 613
2 HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients Wenting Guo et al. · Nature Communications Open access 5 Oct 2017 389
3 Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Casey N. Cook, Yari Carlomagno, Tania F. Gendron et al. · Human Molecular Genetics Open access 19 Aug 2013 306
4 Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma Dan T. Vogl, Noopur S Raje, Sundar Jagannath et al. · Clinical Cancer Research Open access 4 Jan 2017 256
5 Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial Andrew Jenho Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology 17 Sep 2016 204
All 72 most cited papers, with filters and sorting

Which keywords describe research at Acetylon Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Epigenetic Regulation, Gene Expression, HDAC Inhibitors, Histone Deacetylases, Transcriptional Regulation, BET Bromodomains and PROTACs.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 38 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 38 words, with their numbers
  1. Cancer Therapy14▲ 55×3 topics
  2. Epigenetic Regulation12▲ 142×2 topics
  3. Gene Expression11▲ 43×2 topics
  4. HDAC Inhibitors11▲ 1369×1 topic
  5. Histone Deacetylases11▲ 1369×1 topic
  6. Transcriptional Regulation9▲ 88×4 topics
  7. BET Bromodomains7▲ 857×1 topic
  8. PROTACs7▲ 857×1 topic
  9. Staging System3▲ 132×2 topics
  10. PET Imaging3▲ 35×2 topics
  11. Angiogenesis3▲ 18×3 topics
  12. Proteasome Inhibitors3▲ 105×2 topics
  13. Tumor Microenvironment3▲ 21×3 topics
  14. DNA Methylation3▲ 61×1 topic
  15. Histone Modification3▲ 109×1 topic
  16. Fibroblast Activation Protein3▲ 134×1 topic
  17. Immunosuppression3▲ 59×1 topic
  18. Minimal Residual Disease3▲ 95×2 topics
  19. Diagnosis Criteria2▲ 194×1 topic
  20. Epidemiology2▲ 1.48×5 topics
  21. International Myeloma Working Group2▲ 194×1 topic
  22. Cancer2▲ 3.9×5 topics
  23. Sickle-cell Disease2▲ 104×1 topic
  24. Thalassemia2▲ 104×1 topic
  25. Prognostic Factors2▲ 11×3 topics
  26. Arginine Methylation2▲ 124×1 topic
  27. Protein Arginine Methyltransferases2▲ 124×1 topic
  28. Metastatic Breast Cancer2▲ 59×2 topics
  29. Hematopoietic Stem Cells2▲ 36×2 topics
  30. Quality of Life2▲ 2.7×4 topics
  31. AML1▲ 73×1 topic
  32. Acute Myeloid Leukemia1▲ 73×1 topic
  33. Genetic Mutations1▲ 6.3×4 topics
  34. Chemotherapy-Induced Peripheral Neuropathy1▲ 54×1 topic
  35. Immunotherapy1▲ 4.1×2 topics
  36. Taxanes1▲ 54×1 topic
  37. ALK1▲ 74×1 topic
  38. Neuroblastoma1▲ 74×1 topic

Which research topics does Acetylon Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Glycogen Storage Diseases and Myoclonus, Trypanosoma species research and implications, Lysosomal Storage Disorders Research and Dental Health and Care Utilization.

Glycogen Storage Disease…0Glycogen Storage Diseases and Myoclonus: 0 fractional worksTrypanosoma species rese…0Trypanosoma species research and implications: 0 fractional worksLysosomal Storage Disord…0Lysosomal Storage Disorders Research: 0 fractional worksDental Health and Care U…0Dental Health and Care Utilization: 0 fractional worksDental Anxiety and Anest…0Dental Anxiety and Anesthesia Techniques: 0 fractional worksNeuroethics, Human Enhancement, Biomedical Innovations: 0 fractional works
RheumatologyEpidemiologyPhysiologyPeriodontics2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Glycogen Storage Diseases and Myoclonus Rheumatology 0 works
  2. 2 Trypanosoma species research and implications Epidemiology 0 works
  3. 3 Lysosomal Storage Disorders Research Physiology 0 works
  4. 4 Dental Health and Care Utilization Periodontics 0 works
  5. 5 Dental Anxiety and Anesthesia Techniques Oral Surgery 0 works
  6. 6 Neuroethics, Human Enhancement, Biomedical Innovations Cognitive Neuroscience 0 works
  7. 7 Pain Management and Opioid Use Anesthesiology and Pain Medicine 0 works
  8. 8 Pain Mechanisms and Treatments Physiology 0 works
  9. 9 Peptidase Inhibition and Analysis Oncology 0 works
  10. 10 Protein Degradation and Inhibitors Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available23.9%not open76.1%

World: 40% of research is openly available.

with international co-authors11.5%domestic only88.5%

World: 18% is written across borders.

How has Acetylon Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 49% lower than in 2018-2021.

20152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Acetylon Pharmaceuticals (United States) as a percentage of every work published that year, 0.0000067% in 2022.

0.00010%0.00020%0.00030%Acetylon Pharmaceuticals (United States)0.000012% in 20232020

Fractional works of Acetylon Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Boston

All research institutions in Boston

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Acetylon Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.